From GlobeNewswire: 2025-05-23 05:40:00

Orion Oyj and Shilpa Medicare have reached an agreement on the rights to market recombinant human serum albumin in Europe. This albumin is a key plasma protein used for various medical purposes and is produced using biotechnological methods by Shilpa. Orion will have exclusive rights to distribute, market, and sell the product in Europe, with Shilpa receiving milestone payments for development and approval. This partnership aims to bring innovative biologics to patients across Europe and strengthen both companies’ presence in regulated markets. Orion is a Finnish pharmaceutical company with a focus on cancer and pain therapy, with a revenue of €1.542 billion in 2024 and around 3,700 employees worldwide.



Read more at GlobeNewswire: Orion ja Shilpa Medicare sopimukseen rekombinantti